Roche’s giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of Medicine
Basel, 1 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that detailed results from the evERA Breast Cancer study, showing investigational giredestrant in combination with everolimus significantly improved progression-free survival (PFS) versus standard endocrine therapy plus everolimus, were published in The New England Journal of Medicine (NEJM). The evERA trial is evaluating giredestrant, an investigational oral selective oestrogen receptor degrader (SERD), in combination with everolimus in people with oestrogen receptor (ER)-positive locally advanced or metastatic breast cancer who had disease progression or recurrence following treatment with a cyclin-dependent kinase (CDK)4/6 inhibitor and endocrine therapy.1
Covered in this story
What has happened since
- Information Services Group Inc is up 1.4% since this was published, 19 days ago.
- Roper Technologies is up 9.8% since this was published, 19 days ago.
- Provident Financial Services Inc is up 0.9% since this was published, 19 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $ROG.SW yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Roche Holding →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.